The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

Recreational ketamine use has increased in the United States in recent years, outpacing its rise as a treatment for depression, a new analysis suggests. The hallucinogenic drug — a controlled ...

Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...